Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

TGen-led study lays groundwork for using cfDNA to monitor glioblastoma

Cell-free DNA fragments shed into circulating blood may provide an important biomarker for monitoring the progression and treatment of glioblastoma, a highly aggressive brain cancer, according to a study by researchers at TGen, part of City of Hope, and the Mayo Clinic.

October 09, 2026

Vol.52 No.37

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

In Brief

Jason Zhang receives V Foundation grant to uncover how glioblastoma evades treatment

Jason Zhang, an assistant professor of bioengineering in the UCLA Samueli School of Engineering and a member of the UCLA Health Jonsson Comprehensive Cancer Center, has received an $800,000 grant from the V Foundation for Cancer Research to investigate how glioblastoma cells become resistant to targeted treatments.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

Bristol Myers Squibb on Sept. 8 announced positive phase II results from the registrational QUINTESSENTIAL trial (NCT06297226) of arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM).

September 18, 2026

Vol.52 No.34

Clinical Roundup

GABA boosts cancer-protecting immune cells in females with glioblastoma, preclinical study finds

Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.

June 26, 2026

Vol.52 No.25

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

YOU MAY BE INTERESTED IN

TGen-led study lays groundwork for using cfDNA to monitor glioblastoma

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Jason Zhang receives V Foundation grant to uncover how glioblastoma evades treatment

Registrational phase II trial of arlo-cel meets primary endpoint in RRMM

GABA boosts cancer-protecting immune cells in females with glioblastoma, preclinical study finds

Renew today!

Subscriber content

Never miss an issue!

Login